Free tool
FAERS Monitor: Thyrogen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 020898 or its brand name (Thyrogen, Thyrotropin Alfa). Reports on generic versions are filed under their own applications.
Reports
1,038
Serious
353
34% of reports
Hospitalization
161
Death reported
23
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea130
- headache83
- fatigue82
- off label use81
- vomiting53
- malaise43
- dizziness41
- pain41
- drug ineffective38
- blood thyroid stimulating hormone decreased28
- asthenia26
- pyrexia26
- diarrhoea24
- product storage error24
- arthralgia23
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 7 |
| 2006 | 14 |
| 2007 | 19 |
| 2008 | 13 |
| 2009 | 17 |
| 2010 | 24 |
| 2011 | 13 |
| 2012 | 20 |
| 2013 | 66 |
| 2014 | 61 |
| 2015 | 59 |
| 2016 | 66 |
| 2017 | 61 |
| 2018 | 40 |
| 2019 | 65 |
| 2020 | 49 |
| 2021 | 74 |
| 2022 | 76 |
| 2023 | 70 |
| 2024 | 102 |
| 2025 | 61 |
| 2026 | 46 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,121 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood thyroid stimulating hormone decreasedSignal | 28 | 125.7 | 87.1 | 3,320 |
| product storage errorSignal | 24 | 5.6 | 3.7 | 86 |
| nauseaSignal | 130 | 3.3 | 2.8 | 218 |
| headacheSignal | 83 | 2.7 | 2.2 | 89 |
| vomitingSignal | 53 | 2.3 | 1.8 | 38 |
| fatigueSignal | 82 | 2.1 | 1.7 | 50 |
| malaise | 43 | 2.0 | 1.5 | 21 |
| off label use | 81 | 1.9 | 1.5 | 34 |
| dizziness | 41 | 1.7 | 1.2 | 11 |
| pyrexia | 26 | 1.5 | 1.0 | 4 |
| asthenia | 26 | 1.4 | 1.0 | 3 |
| pain | 41 | 1.4 | 1.0 | 4 |
| arthralgia | 23 | 1.1 | 0.7 | 0 |
| diarrhoea | 24 | 0.8 | 0.5 | 2 |
| drug ineffective | 38 | 0.6 | 0.4 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.